Hydroxyethyl starch
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Hydroxyethyl starch
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | 130 kDa (mean) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 1.4 hrs |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. It is one of the most frequently used blood plasma substitutes under the trade names Hespan by B. Braun Medical Inc. and Voluven by Fresenius Kabi. It is also used in oil drilling.
Therapeutic use
An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood caused by trauma, surgery, or some other problem. It increases the blood volume, allowing red blood cells to continue to deliver oxygen to the body.
Contraindications
- This product should not be used in people who are hypersensitive or allergic to hydroxyethyl starch.
- Patients with kidney failure not related to low blood volume and patients on dialysis should avoid this product.
- Use is contraindicated in people with severe increases in blood levels of sodium or chloride.
- Patients with bleeding inside the head should not use this product.
Pharmacokinetics
The elimination depends on molar substitution degree. Molecules smaller than the renal threshold (60–70 kDa) are readily excreted in the urine while the larger ones are metabolized by plasma α–amylase before the degradation products are renally excreted.
Adverse effects
Anaphylactoid reactions: hypersensitivity, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm and non-cardiogenic pulmonary edema.
Decrease in hematocrit and disturbances in coagulation. May be associated with covering the use of anabolic steroids/EPO for endurance athletes.
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
